Written by 11:59 am Business Consultant, Pharma Consultant, The Business Cocktail

The Business Cocktail

vedanta

Vedanta raises USD 27 Million to move microbiome assets through th clinic

Vedanta Biosciences raises USD 27 million in its series C round. The cash will bolster its microbiome-derived drugs pipeline. The capital will aid a phase 1/2 trial of VE416 in food allergy, a phase 2 study of VE303 in recurrent C. difficile infection and a phase 1b/2 study of VE800 in combination with Bristol-Myers Squibb’s Opdivo in advanced or metastatic cancers. The funding comes from the Bill & Melinda Gates Foundation, Bristol-Myers Squibb, Rock Springs Capital, Invesco Asset Management, Seventure Partners, and PureTech Health

Relay Therapeutics reels in USD 400 Million to accelerate discovery

Relay Therapeutics is bagged a massive USD 400 million series C round to ramp up its platform technology and discovery efforts, build its pipeline and push itself into the clinic. Before launching out of Third Rock Ventures with a USD 57 million series A, the company worked silently for about a year, mission is to create new treatments against targets that were previously considered undruggable, with an initial focus on cancer. Relay is looking to modulate these changes to create next-generation treatments for cancer.

Gene therapy could be cost effective in spinal muscular atrophy (SMA)

Biogen’s Spinraza was approved by the FDA as the first and only disease-modifying treatment for SMA, a rare and often fatal genetic muscular disorder. The price tag is USD 750,000 for the first year of therapy. Though high, a report by the Institute for Clinical and Economic Review (ICER) has suggested Zolgensma, Novartis’ experimental SMA gene therapy. It could be more cost-effective in the long run versus Spinraza. Zolgensma is currently under FDA review.

(Visited 7 times, 1 visits today)
Close